CL2025001237A1 - Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos - Google Patents

Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos

Info

Publication number
CL2025001237A1
CL2025001237A1 CL2025001237A CL2025001237A CL2025001237A1 CL 2025001237 A1 CL2025001237 A1 CL 2025001237A1 CL 2025001237 A CL2025001237 A CL 2025001237A CL 2025001237 A CL2025001237 A CL 2025001237A CL 2025001237 A1 CL2025001237 A1 CL 2025001237A1
Authority
CL
Chile
Prior art keywords
autoantibody
treatment
immunoglobulin
multispecific molecules
induced diseases
Prior art date
Application number
CL2025001237A
Other languages
English (en)
Inventor
Siva Charan Devanaboyina Venkata
Li Peng
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2025001237A1 publication Critical patent/CL2025001237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a moléculas multiespecíficas que se unen a inmunoglobulina y a una diana de reciclaje. La unión de la inmunoglobulina y una diana de reciclaje da como resultado la degradación de la inmunoglobulina y, en ciertas realizaciones, el reciclaje de la molécula multiespecífica. Se cree que las moléculas multiespecíficas de la presente invención son útiles en el tratamiento de enfermedades inducidas por autoanticuerpos.
CL2025001237A 2022-10-26 2025-04-25 Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos CL2025001237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263419549P 2022-10-26 2022-10-26

Publications (1)

Publication Number Publication Date
CL2025001237A1 true CL2025001237A1 (es) 2025-06-23

Family

ID=88874631

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001237A CL2025001237A1 (es) 2022-10-26 2025-04-25 Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos

Country Status (10)

Country Link
US (1) US20260042865A1 (es)
EP (1) EP4608864A1 (es)
JP (1) JP2026500893A (es)
KR (1) KR20250094708A (es)
CN (1) CN120359240A (es)
AU (1) AU2023367846A1 (es)
CL (1) CL2025001237A1 (es)
IL (1) IL320335A (es)
MX (1) MX2025004882A (es)
WO (1) WO2024092033A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146152A1 (zh) * 2024-01-04 2025-07-10 上海宝济药业股份有限公司 一种药物组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
AU2017366674B2 (en) * 2016-12-02 2025-01-02 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
US20230183379A1 (en) * 2018-11-20 2023-06-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
US20220023434A1 (en) * 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
EP4251130A4 (en) * 2020-11-30 2024-12-11 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
US20240309084A1 (en) * 2021-01-19 2024-09-19 Novartis Ag Degradation of extracellular targets

Also Published As

Publication number Publication date
JP2026500893A (ja) 2026-01-09
IL320335A (en) 2025-06-01
MX2025004882A (es) 2025-06-02
KR20250094708A (ko) 2025-06-25
AU2023367846A1 (en) 2025-05-01
CN120359240A (zh) 2025-07-22
US20260042865A1 (en) 2026-02-12
EP4608864A1 (en) 2025-09-03
WO2024092033A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
CL2022003077A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
MX2021000398A (es) Moleculas de anticuerpo que se unen a pd-l1 y cd137.
CO2022011332A2 (es) Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
MX2022002977A (es) Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.
MX2019003225A (es) Proteínas de unión a cd123 y composiciones y métodos relacionados.
PE20190907A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
ECSP24044371A (es) Moléculas de anticuerpo y conjugados
CL2023001735A1 (es) Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas
MX2011010707A (es) Anticuerpos dkk-1.
CL2023000683A1 (es) Moléculas de unión a b7-h4 terapéuticas
CO2024003967A2 (es) Proteínas que se unen a nkg2d, cd16 y baff-r
BR112022013575A2 (pt) Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
MX2024008174A (es) Metodos para tratar el cancer urotelial musculo-invasivo o el cancer de vejiga musculo-invasivo con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
MX2023010813A (es) Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco.
MX2021009533A (es) Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo.
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
MX2025004882A (es) Moleculas multiespecificas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos
MX2022005717A (es) Moleculas de anticuerpos anti-siglec-9.
CL2020000755A1 (es) Moléculas de unión a antígeno biespecíficas que se unen a un antígeno blanco de staphylococcus y a un componente del complemento y usos de las mismas.